Research programme: immunotherapeutic vaccines - Scancell

Drug Profile

Research programme: immunotherapeutic vaccines - Scancell

Alternative Names: Modi-1; PAP vaccine - Scancell; PAP-114; SCIB-2; SCMod 1

Latest Information Update: 05 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Scancell
  • Developer Karolinska Institute; Scancell
  • Class Cancer vaccines; DNA vaccines; Protein-vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer
  • Research Rheumatoid arthritis
  • Discontinued Infections

Most Recent Events

  • 26 Jun 2017 Scancell has patent protection for DNA ImmunoBody® platform technology in European Union
  • 16 Sep 2016 Scancell and the Addario Lung Cancer Medical Institute plan a phase I/II trial for SCIB 2 in Non-small cell lung cancer (Combination therapy)
  • 13 Jul 2016 Scancell plans a clinical trial for Solid tumours
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top